Fibroblastic Stromal Cells Express Receptor Activator of NF-κB Ligand and Support Osteoclast Differentiation
Open Access
- 1 August 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 15 (8) , 1459-1466
- https://doi.org/10.1359/jbmr.2000.15.8.1459
Abstract
Osteoclast formation in bone is supported by osteoblasts expressing receptor activator of NF‐κB ligand (RANKL) and macrophage colony‐stimulating factor (M‐CSF) expression. Numerous osteotropic factors regulate expression levels of RANKL and the RANKL decoy receptor osteoprotegerin (OPG) in osteoblasts, thereby affecting osteoclast differentiation. However, not only is RANKL widely expressed in soft tissues, but osteoclasts have been noted in extraskeletal lesions. We found that cultured skin fibroblastic cells express RANKL, M‐CSF, and OPG messenger (mRNA). Stimulation by 1α,25 dihydroxyvitamin D3 [1,25(OH)2D3] plus dexamethasone (Dex) augmented RANKL and diminished OPG mRNA expression in fibroblastic cells and caused the formation of numerous osteoclasts in cocultures of skin fibroblastic cells with hemopoietic cells or monocytes. The osteoclasts thus formed expressed tartrate‐resistant acid phosphatase (TRAP) and calcitonin (CT) receptors and formed resorption pits in cortical bone. Osteoclast formation also was stimulated (in the presence of Dex) by prostaglandin E2 (PGE2), interleukin‐11 (IL‐11), IL‐1, tumor necrosis factor‐α (TNF‐α), and parathyroid hormone‐related protein (PTHrP), factors which also stimulate osteoclast formation supported by osteoblasts. In addition, granulocyte‐macrophage‐CSF (GM‐CSF), transforming growth factor‐β (TGF‐β), and OPG inhibited osteoclast formation in skin fibroblastic cell‐hemopoietic cell cocultures; CT reduced only osteoclast nuclearity. Fibroblastic stromal cells from other tissues (lung, respiratory diaphragm, spleen, and tumor) also supported osteoclast formation. Thus, RANKL‐positive fibroblastic cells in extraskeletal tissues can support osteoclastogenesis if osteolytic factors and osteoclast precursors are present. Such mesenchymally derived cells may play a role in pathological osteolysis and may be involved in osteoclast formation in extraskeletal tissues.Keywords
This publication has 29 references indexed in Scilit:
- Activated T Lymphocytes Support Osteoclast Formation in VitroBiochemical and Biophysical Research Communications, 1999
- Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoidsJournal of Endocrinology, 1998
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- Giant cells in pigmented villo nodular synovitis express an osteoclast phenotype.Journal of Clinical Pathology, 1997
- Bone Cells Required for Osteoclastic Resorption but Not for Osteoclastic DifferentiationBiochemical and Biophysical Research Communications, 1996
- CELLS OF THE MONONUCLEAR PHAGOCYTE SERIES DIFFERENTIATE INTO OSTEOCLASTIC LACUNAR BONE RESORBING CELLSThe Journal of Pathology, 1996
- Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors.The Journal of Experimental Medicine, 1995
- Preparation and characterization of a mouse osteoclast-like multinucleated cell populationJournal of Bone and Mineral Research, 1992
- Effects of transforming growth factor β1 on the regulation of osteoclastic development and functionJournal of Bone and Mineral Research, 1991
- Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization.Journal of Clinical Investigation, 1986